Blar i forfatter "Grannes, Helene"

Viser treff 1-2 av 2

    • Liraglutide and not lifestyle intervention reduces soluble CD163 after comparable weight loss in obese participants with prediabetes or type 2 diabetes mellitus 

      Grannes, Helene; Ueland, Thor; Simeone, Paola; Liani, Rossella; Guagnano, Maria Teresa; Aukrust, Pål; Michelsen, Annika Elisabet; Birkeland, Kåre Inge; di Castelnuovo, Augusto; Cipollone, Francesco; Halvorsen, Bente; Gregersen, Ida; Santilli, Francesca (Journal article; Tidsskriftartikkel; Peer reviewed, 2024-04-29)
      Background The GLP-1 receptor agonist liraglutide is used to treat hyperglycemia in type 2 diabetes but is also known to induce weight loss, preserve the beta cell and reduce cardiovascular risk. The mechanisms underlying these effects are however still not completely known. Herein we explore the effect of liraglutide on markers of immune cell activity in a population of obese individuals with ...

    • Plasma soluble TIM-3 is increased in normoglycemic South Asian women compared to Nordic women after gestational diabetes mellitus and associated with markers of metaflammation 

      Grannes, Helene; Sharma, Archana; Suntharalingam, Anita; Michelsen, Annika Elisabet; Aukrust, Pål; Ueland, Thor; Birkeland, Kåre Inge; Gregersen, Ida; Lee-Ødegård, Sindre; Halvorsen, Bente (Journal article; Tidsskriftartikkel; Peer reviewed, 2024-11-30)
      Background - Women with South Asian ethnicity have a higher risk of developing type 2 diabetes mellitus (T2DM) compared with white women of European descent, especially after gestational diabetes mellitus (GDM). Central obesity and adipose tissue dysfunction have been linked to their higher risk of T2DM, but the mechanisms are not known. We hypothesize that low-grade, persistent immune cell activation ...